We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

January 31, 2018

In Re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation

View recent docket activity


Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


Coverage

  1. September 13, 2018

    Allergan Looks To Keep CEO's Tribal Patent Docs Out Of MDL

    Documents from Allergan Inc.’s CEO and general counsel on a deal transferring patents to a Native American tribe are at best “marginally relevant” to multidistrict litigation accusing the company of illegally delaying a generic version of dry-eye medication Restasis, the drugmaker told a New York federal judge Wednesday.

1 other articles on this case. View all »

Parties

To view the parties, register now.